A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG

M

Mati Therapeutics

Status and phase

Completed
Phase 2

Conditions

Glaucoma
Ocular Hypertension

Treatments

Drug: Formulation E1 of L-PPDS
Drug: Formulation E2 of L-PPDS

Study type

Interventional

Funder types

Industry

Identifiers

NCT00967811
PPL GLAU 07

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.

Enrollment

83 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects over 18 years of age diagnosed with ocular hypertension or open-angle glaucoma
  • Subjects who have a best corrected visual acuity of 20/100 or better

Exclusion criteria

  • Subjects who wear contact lenses
  • Subjects who have uncontrolled medical conditions
  • Subjects requiring chronic topical artificial tears, lubricants, and/or requiring any other chronic ocular topical medications
  • Subjects who have a history of chronic or recurrent inflammatory eye disease

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

83 participants in 2 patient groups

1. Formulation E1
Experimental group
Description:
Formulation E1 of Latanoprost-PPDS
Treatment:
Drug: Formulation E1 of L-PPDS
2. Formulation E2
Experimental group
Description:
Formulation E2 of Latanoprost-PPDS
Treatment:
Drug: Formulation E2 of L-PPDS

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems